Abstract
Two inhaled anticholinergic agents, ipratropium bromide (Atrovent) and tiotropium bromide (Spiriva), are approved for symptomatic treatment of chronic obstructive pulmonary disease in the U.S. Both agents comply with the Montreal Protocol: ipratropium is now available in a metered-dose inhaler without chlorofluorocarbons, and tiotropium is provided as a dry-powder inhaler. On the basis of controlled clinical studies of up to one year's duration, scheduled maintenance therapy with tiotropium, administered once daily, was found to be more effective than ipratropium given four times daily in producing bronchodilation, reducing dyspnea, improving health status, and lowering the frequency of disease exacerbation.
Original language | English (US) |
---|---|
Pages (from-to) | 150-159 |
Number of pages | 10 |
Journal | P and T |
Volume | 32 |
Issue number | 3 |
State | Published - Mar 2007 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology (medical)